Evommune’s $12.38 share price sits below net cash, but the remaining EVO756 and EVO301 pipeline creates a high-risk binary catalyst trade.
Evommune, Inc. (EVMN) operates as a clinical-stage biotechnology company focused on the discovery, acquisition, and clinical development of transformative therapies designed to halt the progression of chronic inflammatory diseases [cite: 1, 2]. The company targets highly prevalent and underserved markets in systemic dermatology, neurology, and gastroenterology, with primary focus areas on atopic dermatitis (AD), ulcerative colitis (UC), and migraine prophylaxis [cite: 2, 3].
The corporate revenue model is designed around a clinical translation approach [cite: 4]. Rather than operating as a high-risk, early-stage drug discovery engine, the company identifies, in-licenses, and clinicalizes pre-cleared, mid-stage therapeutic candidates that have established safety profiles but have lost operational prioritization at larger biopharmaceutical developers [cite: 4]. Currently pre-revenue with zero commercial product sales, the company generates capital through strategic regional out-licensing agreements, upfront access fees, clinical development milestones, and prospective tiered royalties on future regional sales [cite: 5, 6]. Geographically, the corporate clinical infrastructure directly manages development programs in the United States, Europe, and Canada [cite: 4, 7], while commercial rights in Asian territories, including Japan and Greater China, are monetized through structured out-licensing partnerships, most notably with Maruho Co., Ltd. [cite: 8, 9].
The core product pipeline features two primary clinical assets:
* EVO756: A potent, once-daily, highly selective oral small molecule antagonist of Mas-related G-protein coupled receptor X2 (MRGPRX2), designed to modulate neuroimmune interactions and inhibit mast cell degranulation and sensory nerve activation [cite: 2, 9].
* EVO301: A long-acting, subcutaneously administered SAFA (Serum Albumin-binding Fab-Associated) Interleukin-18 binding protein (IL-18BP) fusion protein designed to neutralize upstream inflammatory processes [cite: 10, 11].
The primary customers for the company’s services are global pharmaceutical organizations seeking late-stage regional or global commercialization rights, and institutional healthcare investors supporting its development programs [cite: 4, 12]. Customers and strategic partners choose the company’s candidates over standard-of-care alternatives because of their unique, dual-action, or upstream mechanisms [cite: 2, 10]. For instance, by targeting MRGPRX2, EVO756 acts directly at the neuroimmune junction to treat both systemic tissue inflammation and peripheral itch, whereas alternative therapies typically focus solely on central nervous pathways or singular downstream cytokines [cite: 2, 13].
The company’s asset development strategy is focused on selective clinical execution [cite: 4]. The lead small-molecule program, EVO756, is an oral antagonist of the MRGPRX2 receptor, which is abundantly expressed on tissue-resident mast cells and peripheral sensory neurons [cite: 2]. Downstream activation of MRGPRX2 by various endogenous ligands triggers immediate, IgE-independent mast cell degranulation and neurogenic inflammation, which drives chronic itch and tissue pathology [cite: 2, 9]. EVO756 blocks this specific receptor, potentially preventing neurogenic itch and underlying chronic inflammation [cite: 2].
Although the asset failed to demonstrate statistical superiority over placebo in a 160-patient Phase 2b trial for chronic spontaneous urticaria (CSU) in June 2026, leading to the discontinuation of development in that specific indication, the trial confirmed the safety and tolerability of the drug [cite: 7, 14]. Consequently, clinical development continues in atopic dermatitis (Phase 2b top-line results expected in the third quarter of 2026) and in migraine prophylaxis (with patient dosing in a Phase 2b trial initiated in mid-2026) [cite: 3, 11].
The second pipeline pillar is EVO301, a long-acting injectable SAFA-IL-18BP fusion protein designed to neutralize aberrantly upregulated IL-18 activity [cite: 11]. Interleukin-18 operates as an upstream alarmin cytokine, acting as a general amplifier of heterogeneous immune pathways, including Th1, Th2, and Th17/22 responses [cite: 15]. Because atopic dermatitis involves highly heterogeneous and complex inflammatory pathways, targeting a single downstream cytokine (such as IL-4 or IL-13) often leaves significant patient populations underserved due to inadequate treatment responses [cite: 15]. EVO301 is engineered to bind native human IL-18 with high affinity and incorporates a serum albumin-binding domain to enable deep tissue penetration and a prolonged therapeutic half-life [cite: 10, 11].
In February 2026, the company reported positive top-line results from a Phase 2a proof-of-concept trial of EVO301 in moderate-to-severe AD [cite: 16, 17]. The trial successfully met its primary endpoint, showing rapid and statistically significant reductions in the Eczema Area and Severity Index (EASI) versus placebo [cite: 17]. Based on this proof-of-concept data, the company plans to optimize the subcutaneous dosing regimen in a larger, placebo-controlled Phase 2b trial expected to begin in mid-2027 [cite: 16].
Operating as a clinical-stage biotechnology entity, the company does not possess traditional commercial moats such as high switching costs, established brand equity, or network effects [cite: 1, 6]. Instead, its competitive advantages are derived from exclusive licensing rights and strong intellectual property [cite: 18]. The core programs were originally in-licensed from Dermira (a subsidiary of Eli Lilly and Company) in January 2021 [cite: 19]. The company holds exclusive global rights for the development and commercialization of these assets, except for select Asian territories sublicensed to Maruho [cite: 8, 10]. This licensing network is supported by composition-of-matter, formulation, and method-of-use patents that protect the core candidates from generic competition [cite: 18, 20].
Additionally, the development of complex biologics like EVO301 requires advanced manufacturing techniques [cite: 10, 11]. The proprietary SAFA fusion protein architecture involves complex mammalian cell expression and purification processes, which represent a significant technical barrier to entry for potential biosimilar developers [cite: 10, 11]. Finally, upon potential regulatory approval, the company will benefit from regulatory exclusivity, including 5 years of Hatch-Waxman exclusivity for new chemical entities (EVO756) and 12 years of biologics exclusivity (EVO301).
The primary market opportunity for the company's pipeline is the systemic Atopic Dermatitis market [cite: 11, 14]. Detailed projections from leading industry databases outline a large and expanding market opportunity:
| Data Source | 2025 Market Size (USD) | Projected Future Market Size (USD) | Compound Annual Growth Rate (CAGR) | Regional and Segment Highlights |
|---|---|---|---|---|
| Precedence Research | $15.92 Billion [cite: 21] | $33.42 Billion by 2035 [cite: 21] | 7.70% (2026–2035) [cite: 21] | North America contributed >36% of revenue in 2025; injectables captured over 48% share [cite: 21]. |
| Towards Healthcare | $6.62 Billion [cite: 22] | $13.96 Billion by 2035 [cite: 22] | 7.75% (2026–2035) [cite: 22] | Segmented by chronic vs. acute types; chronic AD represented ~40% of the market [cite: 22]. |
| Fortune Business Insights | $21.01 Billion [cite: 23] | $46.24 Billion by 2034 [cite: 23] | 9.15% (2026–2034) [cite: 23] | Driven by high diagnosis rates and adoption of targeted systemic biologic therapies [cite: 23]. |
| Grand View Research | $6.95 Billion (U.S. Only) [cite: 24] | $11.94 Billion (U.S. Only) by 2033 [cite: 24] | 6.80% (2026–2033) [cite: 24] | Biologics generated 47.3% of U.S. revenue in 2025; PDE4 inhibitors represent the fastest-growing segment [cite: 24]. |
The systemic therapies segment, particularly injectable biologics, represents the largest and fastest-growing portion of this market [cite: 21, 25]. This growth is driven by the limits of traditional topical therapies and the clinical success of systemic agents [cite: 21, 25]. Consequently, the market opportunity for a highly differentiated subcutaneous biologic like EVO301 is substantial [cite: 10, 11].
The systemic inflammatory and dermatological space is highly competitive, featuring several well-capitalized multinational pharmaceutical companies and clinical-stage biotechnology developers [cite: 24, 26]:
Following the clinical failure of EVO756 in CSU, the company has lost ground in the chronic spontaneous urticaria segment [cite: 7]. However, it remains competitive in atopic dermatitis and migraine prophylaxis, where upcoming Phase 2b data points represent critical valuation catalysts [cite: 11, 26].
The company’s latest reported quarterly financial results are for the first quarter of 2026, ended March 31, 2026, and announced on May 7, 2026 [cite: 16, 33].
The company did not issue near-term revenue or earnings guidance, which is typical for pre-revenue biotechnology firms [cite: 36]. However, management reaffirmed its cash runway guidance [cite: 32, 38]. Following a private placement in February 2026 that generated net proceeds of $117.2 million through the issuance of 4,494,279 shares of common stock at $27.88 per share [cite: 34], the company ended Q1 2026 with $307.0 million in cash, cash equivalents, and short-term and long-term investments [cite: 34, 38]. Management stated that this capital position is sufficient to fund its current operating plan and key clinical development milestones through 2028 [cite: 32, 38].
During the Q1 2026 conference call, management highlighted the progress of its clinical pipeline [cite: 37]. Executives emphasized that the positive Phase 2a proof-of-concept data for EVO301 in AD supported its development plan, with a larger Phase 2b trial utilizing an optimized subcutaneous formulation scheduled to begin in mid-2027 [cite: 16, 38]. Additionally, the company confirmed that BDO USA, P.C. had been ratified by shareholders as its independent registered public accounting firm for the fiscal year ending December 31, 2026 [cite: 39, 40].
The Q1 2026 financial release had a minimal impact on the stock, which fell 4.16% in the subsequent trading session due to general market caution regarding biotech development timelines [cite: 36].
However, the disclosure of the failed Phase 2b trial of EVO756 in chronic spontaneous urticaria on June 29, 2026, had a major impact on the stock [cite: 7]. On the day of the announcement:
* The stock price fell 36.1% in mid-day trading and ended the session down approximately 35% from its previous close of $25.20, closing at $16.45 [cite: 26, 41]. This sell-off erased a significant portion of the company’s market value, with the stock eventually declining to around $12.38 by July 2026 [cite: 42, 43].
* H.C. Wainwright downgraded the stock from Buy to Neutral/Hold, and William Blair downgraded the stock from Outperform to Market Perform, citing reduced confidence in the MRGPRX2 mechanism for itch-related skin diseases [cite: 26, 41, 42].
* In contrast, Morgan Stanley and Clear Street maintained their Buy/Overweight ratings with price targets of $26.00 and $28.00, respectively, arguing that the market had overreacted to the CSU data and was placing little value on the upcoming Phase 2b readout in Atopic Dermatitis and the long-term potential of the IL-18 program, EVO301 [cite: 41, 42, 44].
To evaluate the company’s current market valuation, the capital structure and key valuation metrics are detailed in the table below:
Total Capitalization & Balance Sheet Metrics (As of Q1 2026)
+------------------------------------------+---------------------+
| Financial Metric | Value (USD) |
+------------------------------------------+---------------------+
| Cash, Cash Equivalents & Investments | $307.0 Million | [cite: 34, 38]
| Total Assets | $322.5 Million | [cite: 16]
| Total Liabilities | $17.9 Million | [cite: 16]
| Common Stock Outstanding (May 5, 2026) | 36,018,372 Shares | [cite: 34]
| Price-to-Book Ratio | ~1.56x to 2.81x | [cite: 45, 46]
| Short Interest % of Float (July 2026) | 21.36% | [cite: 47]
| Enterprise Value (Post-CSU Selloff) | ~$264.45 Million | [cite: 48]
+------------------------------------------+---------------------+
Traditional valuation metrics like Price-to-Sales or Enterprise Value-to-Revenue are not reliable indicators of value for a pre-revenue biotechnology company [cite: 36, 44]. Instead, the company's valuation is driven by its cash balance and the probability-weighted value of its clinical assets [cite: 26, 44].
With cash and investments of $307.0 million and total liabilities of only $17.9 million, the company has a net cash position of approximately $289.1 million [cite: 16, 34]. Comparing this to its post-selloff enterprise value of approximately $264 million suggests that the market is valuing the remaining clinical assets (EVO756 in Atopic Dermatitis/migraine and EVO301 in AD) at a negative implied enterprise value [cite: 34, 48]. This discount indicates that the stock may be undervalued relative to its cash position and upcoming clinical data points, such as the Phase 2b atopic dermatitis readout in the third quarter of 2026 [cite: 11, 44].
The company’s execution risks are centered on its ongoing clinical trials [cite: 5]. Following the failed Phase 2b trial in CSU, the company's clinical-stage viability is heavily dependent on the upcoming Phase 2b trial of EVO756 in atopic dermatitis [cite: 7, 26]. Unlike chronic inducible urticaria, Atopic Dermatitis is a highly heterogeneous inflammatory disease involving multiple, complex cellular pathways [cite: 26, 29]. Clinical experts have noted that targeting Atopic Dermatitis through MRGPRX2 antagonism alone could be less effective due to this biological complexity, which represents a significant risk for the upcoming Q3 2026 data readout [cite: 26, 29].
The systemic inflammatory and dermatological market is highly competitive [cite: 24, 26]. Larger, well-capitalized pharmaceutical companies are actively developing competitive therapies [cite: 26]. For example, Incyte’s clinical development of EP262 represents a direct competitive threat to EVO756 [cite: 27, 28]. If Incyte can accelerate its clinical timelines or demonstrate superior efficacy, the market potential of the company’s MRGPRX2 antagonist program could be limited [cite: 28].
The company relies on its strategic partnership with Maruho Co., Ltd. to commercialize and develop EVO756 in Asian territories, including Japan and Greater China [cite: 8, 9]. The Maruho Greater Asia agreement represents a potential source of non-dilutive development milestones up to $61.5 million, with $7.0 million received as of Q1 2026 [cite: 34]. If Maruho terminates the agreement or shifts its developmental focus away from MRGPRX2 antagonists, the company would lose a key source of non-dilutive capital and commercial access to Asian markets [cite: 9, 49].
The company faces strict regulatory oversight from the FDA and international regulatory agencies, and there is no guarantee that its candidates will receive marketing approvals [cite: 6].
Additionally, the company faces corporate governance and legal risks [cite: 50]. Levi & Korsinsky, LLP initiated an investigation into potential securities law violations and breach of fiduciary duties by the company's officers and directors [cite: 50, 51]. The investigation focuses on whether corporate insiders possessed material, non-public information regarding the failed Phase 2b CSU trial when they executed significant stock sales on June 22, 2026, just one week before the clinical failure was announced on June 29, 2026 [cite: 50]. These sales, executed by CEO Luis Peña, Chief Scientific Officer Jeegar Patel, and Chief of Development Operations Janice Drew, were disclosed on Form 4 filings and attributed to Rule 10b5-1 trading plans adopted in early March 2026 [cite: 50, 52, 53]. If this investigation leads to class-action securities litigation or regulatory penalties, it could result in financial liabilities, reputational damage, and significant executive distraction.
The company is currently burning cash at a rapid rate, with a net cash outflow from operating activities of $27.5 million in the first quarter of 2026 [cite: 34]. While its current cash reserves of $307.0 million provide a runway through 2028, conducting larger Phase 3 clinical trials is highly expensive [cite: 6, 16, 34]. If the company cannot secure non-dilutive licensing upfronts from global partnerships, it will need to raise additional capital through dilutive equity offerings, which would dilute existing shareholders [cite: 6, 43].
Operating as a clinical translation company, the business model relies on licensing pre-cleared candidates rather than maintaining an early-stage drug discovery engine [cite: 4]. This structural approach reduces early-stage discovery risk but makes the company highly dependent on a small number of clinical programs [cite: 4]. This concentrated pipeline structure increases the binary nature of the company’s investment profile [cite: 4, 54].
The company is sensitive to broader macroeconomic indicators, particularly interest rates and biotechnology funding cycles [cite: 6]. Elevated interest rates increase the discount rate applied to future cash flows, which disproportionately impacts the valuations of pre-revenue biotechnology firms. Tight credit markets can also restrict the company’s ability to access capital on favorable terms, increasing the cost of dilutive financing [cite: 6].
Risk Horizon & Identification Framework
+-------------------------------------+-------------------------------------+-------------------------------------+
| Risk Category | Early Warning Sign | Long-Term Thesis Killer |
+-------------------------------------+-------------------------------------+-------------------------------------+
| Clinical execution risk [cite: 5] | Marginal or inconclusive data from | Clinical trial failures of both |
| | the Phase 2b trial in AD [cite: 26].| EVO756 and EVO301 [cite: 54]. |
+-------------------------------------+-------------------------------------+-------------------------------------+
| Legal & Governance risk [cite: 50] | The filing of formal securities | Regulatory sanctions or executive |
| | class-action lawsuits [cite: 50]. | turnover due to insider trading |
| | | investigations [cite: 50]. |
+-------------------------------------+-------------------------------------+-------------------------------------+
| Balance sheet risk [cite: 6] | Uncontrolled increases in quarterly | Inability to secure global partners |
| | operational cash burn [cite: 34]. | for late-stage development, leading |
| | | to severe dilution [cite: 6, 43]. |
+-------------------------------------+-------------------------------------+-------------------------------------+
The following 5-year scenario analysis projects the potential valuation and share price of the company by 2031, based on the current outstanding share count of 36,018,372 shares as of May 2026 [cite: 34] and a current stock price of $12.38 USD [cite: 42].
Using the subjective probability weights (25% High, 50% Base, 25% Low), the probability-weighted 5-year target price is calculated as follows:
$\text{Weighted Target Price} = (\$60.76 \times 0.25) + (\$14.81 \times 0.50) + (\$0.60 \times 0.25) = \$15.19 + \$7.41 + \$0.15 = \$22.75\text{ USD}$
| Scenario | Revenue / key scale metric in Year 5 | Margin / earnings assumption | Valuation multiple assumption | Current share price | Implied future share price | 5-year total return | Annualized return | Probability |
|---|---|---|---|---|---|---|---|---|
| High Case | $350.0 Million USD | 50% Net Margin / $175.0M Net Income | 15.0x P/E | $12.38 USD [cite: 42] | $60.76 USD | 390.8% | 37.4% | 25.0% |
| Base Case | $120.0 Million USD | 30% Net Margin / $36.0M Net Income | 20.0x P/E | $12.38 USD [cite: 42] | $14.81 USD | 19.6% | 3.7% | 50.0% |
| Low Case | $0.0 Million USD | N/A | Liquidation Value ($36.0M Cap) | $12.38 USD [cite: 42] | $0.60 USD | -95.2% | -50.1% | 25.0% |
SPECULATIVE BINARY ASSET
To evaluate the non-financial and strategic elements of the company, the following qualitative scorecard is provided. Each metric is scored on a scale of 1 to 10.
The executive team has strong industry experience. CEO Luis Peña directly owns 1.36% of the company (~$6.46 million in value) [cite: 55].
However, corporate governance risks are elevated due to recent insider trading activity. On June 22, 2026, CEO Luis Peña and Chief Scientific Officer Jeegar Patel sold shares just one week before the failed Phase 2b trial results for EVO756 were announced [cite: 50, 53]. While these sales were executed under Rule 10b5-1 trading plans adopted in March 2026, they triggered class-action and securities fraud investigations [cite: 50, 53]. On a positive note, CFO Kyle Carver and Director Arthur Kirsch bought shares in the open market in July 2026 at lower prices (~$13.30), indicating some insider confidence [cite: 7, 56, 57].
The quality of current revenue is low. As a pre-revenue clinical biotech, the company does not have stable, recurring product sales [cite: 36]. Its historical revenues consist of non-recurring licensing fees and milestones from partners like Maruho [cite: 5, 8]. This results in lumpy revenue streams, as shown by revenue dropping to zero in Q1 2026 after recognizing $3.0 million in Q1 2025 [cite: 16].
The company’s market position has weakened. The failure of EVO756 in chronic spontaneous urticaria eliminated its opportunity to challenge Novartis in the hives market, shifting that entire potential market share to Novartis' approved drug, Rhapsido [cite: 26, 29]. In Atopic Dermatitis, the company is a late entrant, trailing far behind established standard treatments like Dupixent [cite: 26, 32]. However, the positive early proof-of-concept data for EVO301 supports its competitive potential in the systemic AD market [cite: 16, 17].
The company's growth outlook is highly binary, depending entirely on clinical milestones [cite: 54]. If the upcoming Phase 2b AD readout for EVO756 in Q3 2026 is successful, or if EVO301 moves smoothly into its planned Phase 2b trial, the growth profile will improve significantly [cite: 11, 14]. Conversely, a failure in the AD trial would leave the company with limited growth prospects [cite: 26].
Financial health is a key strength. The company has a solid cash balance of $307.0 million as of March 31, 2026, which was boosted by the $125 million private placement in February 2026 [cite: 34]. The company has low long-term debt and liabilities of only $17.9 million [cite: 16]. This strong financial position provides an operational runway through 2028, which is a significant advantage for a micro-cap biotechnology company [cite: 32, 38].
The company's long-term durability is limited. The company's viability is tied directly to the clinical progression of its two key assets, EVO756 and EVO301 [cite: 11, 54]. If these assets fail to gain regulatory approvals, the company has no other major clinical-stage candidates to fall back on, creating a significant strategic risk [cite: 2].
The capital allocation strategy is logical. It focuses on in-licensing pre-cleared, clinical-stage assets from larger pharmaceutical firms (such as Dermira/Eli Lilly and AprilBio) to avoid early-stage drug discovery risk and move straight to proof-of-concept trials [cite: 4, 10, 13]. However, the recent clinical failure of EVO756 in CSU shows that underwriting in-licensed clinical assets remains highly risky [cite: 7].
Analyst sentiment is mixed. Following the failed CSU trial in June 2026, William Blair and H.C. Wainwright downgraded the stock to Neutral/Hold [cite: 26, 41, 42]. However, several investment banks, including Morgan Stanley, Clear Street, and RBC Capital, maintained Buy/Overweight ratings with price targets ranging from $26.00 to $54.00, suggesting that the stock may be undervalued at current levels [cite: 41, 42].
The company is unprofitable, with net losses of $21.7 million in Q1 2026 [cite: 16] and $68.9 million in fiscal year 2025 [cite: 58]. Its accumulated deficit stood at $221.1 million as of December 31, 2025 [cite: 6]. This is typical for a clinical-stage biotechnology company [cite: 6, 36].
The management team has a solid track record, having previously guided Dermira to a $1.1 billion acquisition by Eli Lilly in 2020 [cite: 12, 19]. However, as a public entity, the company has struggled to create shareholder value since its November 2025 IPO at $16.00, with the stock currently trading down to $12.38 [cite: 1, 42].
Combining these metrics, the company receives a Blended Qualitative Score of 4.6 / 10. This score reflects the company's strong financial health and solid cash runway, which are offset by high binary clinical risks, a lack of recurring revenues, and ongoing corporate governance and legal investigations [cite: 6, 34, 50].
SPECULATIVE BINARY ASSET
The investment thesis for the company is highly speculative and presents a binary risk-reward profile [cite: 6, 44]. The structural changes following the clinical failure of EVO756 in CSU have consolidated its operational focus [cite: 7, 14]. By terminating the CSU development program, management has reduced operational burn on a failed indication and focused resources on remaining assets where clinical signals are stronger [cite: 7, 32].
At its current price of $12.38 USD, the market is assigning a negative enterprise value to the company’s remaining pipeline, valuing the stock below its net cash position [cite: 34, 42, 48]. This discount represents an entry point for speculative investors, supported by the following near-term catalysts:
1. Phase 2b Atopic Dermatitis Readout for EVO756: Expected in the third quarter of 2026, this data point will serve as a key test of the MRGPRX2 mechanism in chronic skin conditions [cite: 3, 11].
2. Phase 2b Subcutaneous Dosing Optimization for EVO301: Scheduled to begin in mid-2027, this trial represents a key catalyst for entering the systemic Atopic Dermatitis market with a subcutaneously administered biologic [cite: 16].
3. Phase 2b Migraine Prophylaxis Trial: The initiation of patient dosing in mid-2026 provides a long-term development pipeline outside of dermatological indications [cite: 3, 11].
While the cash runway through 2028 is a significant risk-mitigating factor, investors must carefully monitor the high risk of clinical trial failures, prospective dilution after 2028, and the potential impact of ongoing class-action investigations into executive stock sales [cite: 6, 43, 50].
Speculative Pipeline Asset
The stock is in a strong technical downtrend [cite: 59]. Following the failed CSU trial on June 29, 2026, the stock fell below its 50-day moving average of $20.95 and its 20-day EMA of $16.95, establishing a bearish crossover [cite: 59, 60, 61]. The stock is currently trading around $12.38, near its 52-week low of $11.55 to $11.66 [cite: 41, 42, 62].
Technically, the stock is heavily oversold, with its 14-day Relative Strength Index (RSI) at 32.4 and its Stochastic Oscillator indicating a potential short-term bounce as selling pressure slows [cite: 59, 60, 61]. The short-term price action remains dependent on the upcoming Phase 2b Atopic Dermatitis readout expected in the third quarter of 2026, which represents the next major catalyst for the stock [cite: 11, 44].
Oversold Catalyst Watch
View Evommune, Inc. (EVMN) stock page
Loading the interactive version of this report…